Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for argenex (ARGX : NSDQ)
 
 • Company Description   
argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

Number of Employees: 650

 
 • Price / Volume Information   
Yesterday's Closing Price: $319.97 Daily Weekly Monthly
20 Day Moving Average: 405,037 shares
Shares Outstanding: 53.62 (millions)
Market Capitalization: $17,156.47 (millions)
Beta: 1.11
52 Week High: $356.78
52 Week Low: $249.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.30% 14.10%
12 Week 12.13% 23.27%
Year To Date -8.63% 11.64%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Willemstraat 5
-
Breda,P7 4811 AH
NLD
ph: 31-0-10-703-8441
fax: -
info@argenx.com http://www.argenx.com
 
 • General Corporate Information   
Officers
Tim Van Hauwermeiren - Chief Executive Officer
Peter K.M. Verhaeghe - Chairperson
Werner Lanthaler - Vice Chairperson
Pamela Klein - Director
A.A. Rosenberg - Director

Peer Information
argenex (CORR.)
argenex (RSPI)
argenex (CGXP)
argenex (BGEN)
argenex (GTBP)
argenex (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04016X101
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 53.62
Most Recent Split Date: (:1)
Beta: 1.11
Market Capitalization: $17,156.47 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-4.81 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-19.44 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 3.22% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.52
Price/Cash Flow: -
Price / Sales: 42.52
EPS Growth
vs. Year Ago Period: -438.27%
vs. Previous Quarter: 8.40%
Sales Growth
vs. Year Ago Period: -81.20%
vs. Previous Quarter: -29.79%
ROE
03/31/22 - -32.54
12/31/21 - -22.33
09/30/21 - -23.86
ROA
03/31/22 - -29.44
12/31/21 - -20.20
09/30/21 - -20.10
Current Ratio
03/31/22 - -
12/31/21 - 8.44
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - 8.08
09/30/21 - -
Operating Margin
03/31/22 - -147.47
12/31/21 - -75.69
09/30/21 - -73.28
Net Margin
03/31/22 - -147.47
12/31/21 - -75.69
09/30/21 - -73.28
Pre-Tax Margin
03/31/22 - -
12/31/21 - -74.11
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 49.05
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - 0.00
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - -
 

Powered by Zacks Investment Research ©